Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Help Your Insusceptibility: Good dieting and Way of life Tips - 2Getting Your Youngsters' Future: Grasping Legacy Regulations
- 3‘Wicked: For Good’ streaming release — How to watch the sequel starring Ariana Grande and Cynthia Erivo
- 4Which salad do you believe is a definitive group pleaser? Vote!
- 5Study casts doubt on potential for life on Jupiter's moon Europa
- Magnetic fossils may reveal ancient creature's internal 'GPS system'
- Nature: 10 High priority Setting up camp Spots In Europe
- Palestinians tell BBC they were sexually abused in Israeli prisons
- 2024's Hot Games: Must-Play Titles of the Year
- Cocoa Prices Settle Lower on Expectations of Adequate Supplies
- Physicists and philosophers have long struggled to understand the nature of time: Here's why
- US FDA unveils new pathway to approve personalized therapies
- 25 Years Ago, Audi's Rosemeyer Concept Was A Steampunk Supercar With A Massive Engine
- FOX8 Meteorologist Charles Ewing makes his 2025-26 winter weather predictions!
